Table of Contents

Preface ix Acknowledgements x Notes on using The Maudsley Prescribing Guidelines xi Notes on inclusion of drugs xi List of abbreviations xii Chapter 1 Plasma level monitoring of psychotropic drugs and anticonvulsants 1 Interpreting sample results 2 Chapter 2 Schizophrenia 11 Antipsychotic drugs 11 Antipsychotic drugs: equivalent doses 13 Antipsychotic drugs: minimum effective doses 14 Antipsychotic drugs: licensed maximum doses 16 New antipsychotic drugs 17 Antipsychotic drugs: general principles of prescribing 21 National Institute for Health and Clinical Excellence guidelines for the treatment of schizophrenia 22 Treatment algorithms for schizophrenia 24 Antipsychotic drugs: monitoring of metabolic effects 26 Switching antipsychotic drugs because of poor tolerability 31 Antipsychotic response: to increase the dose, to switch, to add or just wait - what is the right move? 33 Speed and onset of antipsychotic drug action 36 First-generation antipsychotic drugs: place in therapy 39 Antipsychotic drugs: long-acting injections 40 Risperidone long-acting injection 44 Paliperidone palmitate long-acting injection 47 Management of patients on long-term depots: dose reduction 50 Combined antipsychotic drugs 51 High-dose antipsychotic drugs: prescribing and monitoring 54 Negative symptoms in schizophrenia 57 Antipsychotic prophylaxis 60 Refractory schizophrenia and clozapine 64 Clozapine augmentation 66 Refractory schizophrenia: alternatives to clozapine 69 Clozapine: management of common adverse effects 75 Clozapine: uncommon or unusual adverse effects 78 Clozapine: serious haematological and cardiovascular adverse effects 80 Clozapine, neutropenia and lithium 84 Clozapine and chemotherapy 88 Clozapine-related hypersalivation 89 Guidelines for the initiation of clozapine for patients based in the community 92 Omega-3 fatty acids (fish oils) in schizophrenia 96 Extrapyramidal side-effects of antipsychotic drug treatment 98 Treatment of antipsychotic-induced akathisia 103 Treatment of tardive dyskinesia 105 Neuroleptic malignant syndrome 110 Catatonia 113 Cardiovascular effects of antipsychotic drug treatment 115 Antipsychotic drugs and hypertension 122 Hyperprolactinaemia 123 Antipsychotic-induced weight gain 126 Treatment of drug-induced weight gain 128 Antipsychotic drugs, diabetes and impaired glucose tolerance 132 Antipsychotic drugs and dyslipidaemia 138 Antipsychotic drugs and sexual dysfunction 142 Antipsychotic-associated hyponatraemia 148 Antipsychotics and pneumonia 150 Relative adverse effects of antipsychotic drugs: a rough guide 151 Chapter 3 Bipolar disorder 153 Valproate 153 Lithium 159 Carbamazepine 168 Physical monitoring of people with bipolar disorder 173 Treatment of acute mania or hypomania 176 Antipsychotic drugs in bipolar disorder 182 Bipolar depression 185 Rapid cycling bipolar disorder 191 Prophylaxis in bipolar disorder 193 Chapter 4 Depression and anxiety 197 Depression 197 Antidepressants 201 Treatment of resistant depression 222 Treatment of psychotic depression 233 Electroconvulsive therapy and psychotropic drugs 235 Psychostimulants in depression 239 Treatment of depression in the elderly 243 Treatment of depression in stroke 247 Adverse effects of antidepressants 249 Selective serotonin reuptake inhibitors and bleeding 252 Depression and diabetes 255 Cardiac effects of antidepressants 257 Antidepressants and sexual dysfunction 264 Antidepressants and hyperprolactinaemia 268 Antidepressants: swapping and stopping 270 St John's wort in the treatment of depression 278 Drug interactions with antidepressants 281 Alternative routes of administration for antidepressants 286 Anxiety spectrum disorders 292 Benzodiazepines in the treatment of psychiatric disorders 301 Benzodiazepines and disinhibition 304 Benzodiazepines: dependence and detoxification 306 Insomnia 310 Chapter 5 Children and adolescents 315 Principles of prescribing practice in childhood and adolescence 315 Depression in children and adolescents 316 Bipolar illness in children and adolescents 321 Psychosis in children and adolescents 326 Anxiety in children and adolescents 327 Obsessive compulsive disorder in children and adolescents 328 Attention deficit hyperactivity disorder 332 Autism spectrum disorders 337 Tics and Tourette's syndrome 345 Melatonin in the treatment of insomnia in children and adolescents 349 Rapid tranquillisation in children and adolescents 351 Doses of commonly used psychotropic drugs in children and adolescents 354 Chapter 6 Substance misuse 355 Alcohol dependence 356 Opioid misuse and dependence 372 Nicotine and smoking cessation 398 Stimulant drugs of dependence 406 Benzodiazepine misuse 407 -Butaryl-lactone and -hydroxybutyrate dependence 408 Drugs of misuse: a summary 410 Interactions between 'street drugs' and prescribed psychotropic drugs 414 Chapter 7 Use of psychotropic drugs in special patient groups 419 Epilepsy 419 Pregnancy 430 Breast feeding 446 Renal impairment 462 Hepatic impairment 478 Prescribing in the elderly 487 Dementia 490 Behavioural and psychological symptoms of dementia 509 Parkinson's disease 518 Multiple sclerosis 522 Eating disorders 527 Acutely disturbed or violent behaviour 531 Psychotropic medications for adults with learning disabilities 539 Borderline personality disorder 545 Delirium 547 Huntington's disease 554 Psychotropic drugs and surgery 558 Prescribing psychotropic drugs for patients with HIV infection 564 Psychotropic drugs and cytochrome (CYP) function 573 Summary of psychiatric side-effects of non-psychotropic drugs 578 Chapter 8 Miscellaneous conditions and substances 587 Psychotropic drugs in overdose 587 Biochemical and haematological effects of psychotropic drugs 593 Prescribing drugs outside their licensed indications 604 Observations on the placebo effect in mental illness 606 Drug interactions with alcohol 608 Nicotine 613 Smoking and psychotropic drugs 616 Caffeine 618 Complementary therapies 624 Enhancing medication adherence 628 Driving and psychotropic medicines 634 Covert administration of medicines within food and drink 643 Index 647

About the Author

David Taylor is Director of Pharmacy and Pathology at the South London and Maudsley NHS Foundation Trust, and Professor of Psychopharmacology at King's College London. The lead author of all editions of the Maudsley Prescribing Guidelines, Professor Taylor is the author of several other texts and editor of Therapeutic Advances in Psychopharmacology. Carol Paton is Chief Pharmacist at Oxleas NHS Foundation Trust, London: she is also joint Head of the Prescribing Observatory for Mental Health and an Honorary Research Fellow at Imperial College London. Shitij Kapur is Professor of Schizophrenia, Imaging and Therapeutics and the Dean and Head of School at the Institute of Psychiatry, King's College London.

Reviews

"This comprehensive guide presents clinicians with evidence-based information on prescribing psychotropic drugs for mental health ... This book will help nurses to be confident, sensitive and informed when discussing medication with patients and relatives, exploring treatment options within their professional teams and liaising with allied health professionals." (Nursing Standard, 30 May 2012)